Trials / Unknown
UnknownNCT02085824
Comparison of Blood Loss Following Total Hip Arthroplasty With the Use of Three Thromboprophylactic Regimes: Dabigatran, Enoxaparin and Rivaroxaban.
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Centre of Postgraduate Medical Education · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine which of the following drugs: enoxaparin, dabigatran and rivaroxaban causes least blood loss after total hip replacement (THR).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Enoxaparin | |
| DRUG | rivaroxaban | |
| DRUG | dabigatran |
Timeline
- Start date
- 2012-07-01
- Primary completion
- 2014-04-01
- Completion
- 2014-04-01
- First posted
- 2014-03-13
- Last updated
- 2014-03-14
Locations
1 site across 1 country: Poland
Source: ClinicalTrials.gov record NCT02085824. Inclusion in this directory is not an endorsement.